Search PubMed⌕ Search

Biomedical subjects

H Hosoda

Publications and source records attributed to H Hosoda.

At least 109 records · Page 6Linked to original sources
PubMed1987

[Multimodality treatment of nasopharyngeal carcinoma].

In the treatment of nasopharyngeal carcinoma (NPC), radiation has been the treatment of choice, because it is effective for locoregional disease. However, the results of radiotherapy for NPC have revealed that local relapse and/or distant metastases occur frequently, and consequently the five-year survival rate is as low as around 30%. Since 1982, we have adopted chemotherapy initially applied prior to radiotherapy (= pre-radiation chemotherapy) for the treatment of NPC in order to achieve better results. The chemotherapy mainly consists of a combination of cisplatin and peplomycin. Twenty-one previously untreated patients with NPC were evaluable. Three complete and fifteen partial remissions were achieved, with an 86% response rate to the chemotherapy. The treatment involving a combination of pre-radiation chemotherapy and radiotherapy resulted in local relapse in one patient and distant metastases in two patients with an 87.5% survival rate according to the Kaplan-Meier method. Immunotherapy is also indispensable in the treatment of NPC. Our present multimodality treatment for NPC consists of a combination of pre-radiation chemotherapy and radiotherapy followed by long-term administration of a biologics such as OK-432.

Adolescent↗
PubMed1987

[Multidisciplinary treatment of carcinoma of the oropharynx].

From 1963 through 1986, we examined 91 patients with carcinoma of the oropharynx. Of these 91 patients, the primary treatment modality was chosen for 75 patients. The patients were divided into 2 groups according to the periods of treatment. In group I (1963-1973), 33% of the patients were applied combined radiotherapy and chemotherapy, and 28% chemotherapy followed by surgery as their initial treatment. In group II (1974-1986), 65% of the patients were applied combined radiotherapy and chemotherapy, and 21% a multimodal treatment consisting of radiotherapy combined with chemotherapy followed by composite resection. Five-year survival rate was 36% in group I and 51% in group II, which indicated a progress in the treatment of carcinoma of the oropharynx. The role of surgical treatment for carcinoma of the oropharynx was discussed. It appears that composite resection and reconstructive surgery produced a great benefit in the treatment of residual diseases after radiotherapy or recurrent diseases. Then our new treatment modality incorporating neo-adjuvant chemotherapy was presented. The literatures in terms of neo-adjuvant chemotherapy were reviewed.

Adult↗
PubMed1986

Combination chemotherapy with cisplatin and peplomycin in squamous cell carcinoma of the head and neck.

Ninety-three patients with head and neck cancer were treated with combined cisplatin-peplomycin chemotherapy (CP therapy). Cisplatin (CDDP) 50 mg/m2 i.v. (intravenous) or i.a. (intraarterial) over 2 hr was given with hydration and mannitol diuresis on day 1. From day 2 through day 6, peplomycin (PEP) 5 mg/day was administered by 5-hr i.v. or i.a. infusion, or 24-hr continuous hypodermic injection. Of 85 who were evaluable, there were 22 complete responses or CR (26%) and 36 partial responses or PR (42%), with an overall response rate of 68%. Concerning of the route of administration, i.a. infusion obtained the higher CR and overall response rates than i.v. infusion. Effectiveness was clearly greater in previously untreated cases than in cases that had received some previous therapeutic modality. Looking at response in relation to the number of the courses, at least 2 courses of CP therapy are required. Side effects were recognized in 68 out of 87 evaluable cases (78%). Nausea and vomiting were the most common (62%). Renal toxicity was observed in 24% and was mostly transient. From the above results, it is considered that the CP therapy is effective, not only for the palliative treatment of advanced and recurrent cancer of the head and neck, but also as neo-adjuvant chemotherapy of stage III and IV cases.

Adult↗
PubMed1985

A varnish to prevent etching unrestored enamel.

The prognosis of acid-etched enamel was investigated in both laboratory and clinical experiments. Acid etching produced irregularities even on the prismless layer that covers prism enamel. The irregularities produced by etching are not remineralized in vivo but are filled with organic debris. Brushing reduced the depth of the irregularities but did not eliminate them. A protective varnish against acid etching was developed. The varnish also serves as a guide to facilitate removal of excess resin beyond the cavosurface margin.

Acid Etching, Dental↗
PubMed1985

Neoadjuvant chemotherapy in maxillary sinus carcinoma with cisplatinum and peplomycin intraarterial infusion.

The purpose of this paper is to present our preliminary assessment of a new multimodal treatment including neoadjuvant chemotherapy with cisplatinum and peplomycin for maxillary sinus carcinoma. Fifteen patients with squamous cell carcinoma of the maxillary sinus carcinoma seen at Keio University Hospital, with Stage III and IV disease, were enrolled in this trial between January 1982 and January 1985. Regimen of chemotherapy was as follows: day 1, 50 mg/m2 of cisplatinum, intraarterial infusion over 2 hr, days 2-6, peplomycin at a dose of 5 mg/day, intraarterial infusion over 5 hr. Routinely, radiotherapy of 40 Gy by Linac was given to the primary site, concomitantly combined with 5-fluorouracil intraarterial injections only during the first 10 days, 2 weeks after the end of initial chemotherapy. Additional treatment was performed according to the extent of residual tumor. Response to initial chemotherapy revealed that complete response was achieved in 7 and partial response in 6 out of 15 patients with a response rate of 87%. Nine patients required no surgical intervention while 6 underwent a surgical resection. Median follow-up in this group of patients is 20 months. Thirty-month survival rate calculated by Kaplan-Meier's method was 83%. Chemotherapy toxicity was mild in most cases. This pilot study does not provide conclusive survival information, but the results obtained are encouraging.

Aged↗
PubMed1985

Clinical trials on UFT in the treatment of head and neck cancer.

A new anticancer agent, UFT which is a mixture of 1-(2-tetrahydrofuryl)-5-fluorouracil and uracil in a molar ratio of 1:4 was administered orally at a dose of 600 mg/day every day. Forty-three patients were evaluable. Eight patients achieved a complete response and eight achieved a partial response with an overall response rate of 37.2%. In terms of response by histology, a response rate was 32.4% (11/34) in cases of squamous cell carcinoma and 75% (3/4) in cases of adenocarcinoma. A response rate by primary site was 57.1% in the nose and paranasal sinuses, 50.0% in the oropharynx and 30.0% in the oral cavity. A response rate was 36.1% in patients with prior treatment and 42.9% in patients with no prior treatment, but there was no statistical significance. Eight of 43 patients developed toxic effects. Most of them were mild such as anorexia, nausea, and stomatitis, but in one case of maxillary sinus carcinoma, severe bone marrow suppression was observed. UFT is a considerably effective and useful drug in the treatment of head and neck cancer. It is possible to increase cure rate by examining various usages of UFT.

Adult↗